MOA

EPSG to Unveil and Showcase Expansion of the Company’s Mobile Office Application at Optix Elite 2022 in Saint Martin

Retrieved on: 
Tuesday, November 29, 2022

EPSG, a leading integrator of payment technology solutions, announced today that at Optix Elite 2022, the Company will unveil the latest feature for the Companys Mobile Office Application (MOA), the Merchant Processing Overlay (MPO).

Key Points: 
  • EPSG, a leading integrator of payment technology solutions, announced today that at Optix Elite 2022, the Company will unveil the latest feature for the Companys Mobile Office Application (MOA), the Merchant Processing Overlay (MPO).
  • Optix Elite 2022 is one of EPSGs premier annual events recognizing the achievements of the Companys elite sales partners.
  • This years event is taking place in St. Martin at a luxury boutique hotel on Maho Bay.
  • Matthew Byron, President & COO of EPSG, said: A major focus at EPSG has been the continuous development of the Companys Mobile capabilities.

Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference

Retrieved on: 
Wednesday, November 23, 2022

WOBURN, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY on Thursday, December 1, 2022 at 1:00 PM ET.

Key Points: 
  • WOBURN, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY on Thursday, December 1, 2022 at 1:00 PM ET.
  • Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.
  • Replimunes proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.
  • For more information, please visit www.replimune.com .

Replimune to Host Virtual Investor Event on December 7, 2022

Retrieved on: 
Tuesday, November 22, 2022

Additionally, the company will review the commercial opportunity in skin cancer with RP1.

Key Points: 
  • Additionally, the company will review the commercial opportunity in skin cancer with RP1.
  • The Company will also provide an update on its RP2 and RP3 program.
  • The event will begin at 8:00 a.m. Eastern Time on Wednesday, December 7, 2022.
  • Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.

Global Ulcerated Necrobiosis Lipoidica Market Report to 2032 - Insights, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, November 25, 2022

The "Ulcerated Necrobiosis Lipoidica - Market Insights, Epidemiology, and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ulcerated Necrobiosis Lipoidica - Market Insights, Epidemiology, and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the Ulcerated Necrobiosis Lipoidica, historical and forecasted epidemiology as well as the Ulcerated Necrobiosis Lipoidica market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The Ulcerated Necrobiosis Lipoidica market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM Ulcerated Necrobiosis Lipoidica market size from 2019 to 2032.
  • What would be the Ulcerated Necrobiosis Lipoidica market growth till 2032 and what will be the resultant market size in the year 2032?

JCB and East West Banking Corporation announce the launch of EastWest JCB Credit Card

Retrieved on: 
Thursday, November 10, 2022

TOKYO & MANILA, Nov 10, 2022 - (JCN Newswire) - JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd., Japan's only international payment brand, and East West Banking Corporation announce the launch of EastWest JCB Credit Card, a first for JCB in the Philippines in 25 years.

Key Points: 
  • TOKYO & MANILA, Nov 10, 2022 - (JCN Newswire) - JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd., Japan's only international payment brand, and East West Banking Corporation announce the launch of EastWest JCB Credit Card, a first for JCB in the Philippines in 25 years.
  • EastWest JCB Gold Credit Card and EastWest JCB Platinum Credit Card offer several rewards such as accumulate reward points that can redeem them for airline miles, cash rebates, or annual membership fee waiver.
  • JCB was headed by President and COO of JCB International Yoshiki Kaneko and Yusuke Matsui, JCB Manila's Country Manager.
  • JCB is a major global payment brand and a leading credit card issuer and acquirer in Japan.

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma

Retrieved on: 
Wednesday, November 9, 2022

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported positive preclinical results with its immunotherapy candidate, TTX-siPDL1 , in pancreatic adenocarcinoma.

Key Points: 
  • BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported positive preclinical results with its immunotherapy candidate, TTX-siPDL1 , in pancreatic adenocarcinoma.
  • This is the second drug candidate from TransCodes platform to show positive preclinical results in pancreatic cancer.
  • Pancreatic cancer has proven difficult to treat with conventional drugs and has been resistant to initial immunotherapy approaches.
  • TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics.

Further Education Needed for the Proper Diagnosis of Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in the EU5, Spherix Global Insights Reports

Retrieved on: 
Thursday, November 10, 2022

EXTON, Pa., Nov. 10, 2022 /PRNewswire/ -- Rheumatologists in the EU5 (France, Germany, Italy, Spain, and the United Kingdom) recognize a disconnect in the diagnosis and referral process for ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) patients. The lack of education, awareness of symptoms, and necessary tools needed to properly diagnose these patients has delayed referrals from primary care physicians to rheumatologists.

Key Points: 
  • The lack of education, awareness of symptoms, and necessary tools needed to properly diagnose these patients has delayed referrals from primary care physicians to rheumatologists.
  • Rheumatologists rely on a number of tests and imaging to diagnosis suspected axSpA (axial spondyloarthritis) patients under their care most notably the use of X-rays and MRIs.
  • In fact, only one-quarter of AS patients were referred with the correct diagnosis, which dropped to one-tenth among those with nr-axSpA.
  • To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn and Twitter .

Replimune to Present at Two Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 2, 2022

Replimunes proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.

Key Points: 
  • Replimunes proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.
  • The RPx platform has a unique dual local and systemic mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response.
  • This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options.
  • For more information, please visit www.replimune.com .

Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022

Retrieved on: 
Sunday, October 30, 2022

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended September 30, 2022.

Key Points: 
  • NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended September 30, 2022.
  • The Company plans to have clearance from the FDA by year-end 2022 for the pivotal trial with primary endpoint 12-month reduction in pain.
  • Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets.
  • Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms.

Global Progressive Pulmonary Fibrosis Market to 2032 - Insights, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, October 24, 2022

The "Progressive Pulmonary Fibrosis (PPF) - Market Insights, Epidemiology, and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Progressive Pulmonary Fibrosis (PPF) - Market Insights, Epidemiology, and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This report deliver an in-depth understanding of the Progressive pulmonary fibrosis (PPF), historical and forecasted epidemiology as well as the Progressive pulmonary fibrosis (PPF) market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The Progressive pulmonary fibrosis (PPF) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Progressive pulmonary fibrosis (PPF) market size from 2019 to 2032.
  • Major players are involved in developing therapies for Progressive pulmonary fibrosis (PPF) s. The launch of emerging therapies will significantly impact the Progressive pulmonary fibrosis (PPF) market.